NASDAQ:TBPH Theravance Biopharma - TBPH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $10.52 +0.18 (+1.74%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$10.11▼$10.6050-Day Range$9.87▼$11.4452-Week Range$7.53▼$11.83Volume483,645 shsAverage Volume618,719 shsMarket Capitalization$665.18 millionP/E Ratio0.91Dividend YieldN/APrice Target$16.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Theravance Biopharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside56.8% Upside$16.50 Price TargetShort InterestBearish15.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 3 Articles This WeekInsider TradingSelling Shares$88,120 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.75) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector400th out of 989 stocksPharmaceutical Preparations Industry182nd out of 480 stocks 3.5 Analyst's Opinion Consensus RatingTheravance Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.50, Theravance Biopharma has a forecasted upside of 56.8% from its current price of $10.52.Amount of Analyst CoverageTheravance Biopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.08% of the float of Theravance Biopharma has been sold short.Short Interest Ratio / Days to CoverTheravance Biopharma has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.Change versus previous monthShort interest in Theravance Biopharma has recently decreased by 5.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTheravance Biopharma does not currently pay a dividend.Dividend GrowthTheravance Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TBPH. Previous Next 2.6 News and Social Media Coverage News SentimentTheravance Biopharma has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Theravance Biopharma this week, compared to 1 article on an average week.Search Interest4 people have searched for TBPH on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Theravance Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $88,120.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Theravance Biopharma is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Theravance Biopharma are expected to grow in the coming year, from ($0.75) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theravance Biopharma is 0.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Theravance Biopharma is 0.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.76.Price to Book Value per Share RatioTheravance Biopharma has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Theravance Biopharma (NASDAQ:TBPH) StockTheravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Read More Receive TBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address TBPH Stock News HeadlinesMarch 19, 2023 | americanbankingnews.comTheravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells $23,973.36 in StockMarch 17, 2023 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Now Covered by Analysts at StockNews.comMarch 25, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 16, 2023 | americanbankingnews.comZacks Research Comments on Theravance Biopharma, Inc.'s Q1 2023 Earnings (NASDAQ:TBPH)March 15, 2023 | americanbankingnews.comTheravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum Sells 4,000 Shares of StockMarch 10, 2023 | finance.yahoo.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2022 Earnings Call TranscriptMarch 1, 2023 | bizjournals.comTheravance eyes job, program cuts as shareholder pushes for changesMarch 1, 2023 | finance.yahoo.comTheravance's (TBPH) Q4 Earnings and Revenues Miss EstimatesMarch 25, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!February 27, 2023 | finance.yahoo.comIrenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic ReviewFebruary 27, 2023 | reuters.comExclusive: Irenic Capital urges Theravance to conduct review, add shareholder to boardFebruary 27, 2023 | bizjournals.comActivist investor targets Peninsula biotech, longtime managementFebruary 24, 2023 | msn.comEarnings Preview: Theravance BiopharmaFebruary 21, 2023 | finance.yahoo.comTheravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023February 17, 2023 | seekingalpha.comTBPH Theravance Biopharma, Inc.January 9, 2023 | finance.yahoo.comTheravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key TargetsDecember 25, 2022 | finance.yahoo.comShareholders in Theravance Biopharma (NASDAQ:TBPH) are in the red if they invested five years agoDecember 7, 2022 | finance.yahoo.comWhy Is Theravance Bio (TBPH) Up 1.6% Since Last Earnings Report?November 18, 2022 | finance.yahoo.comTheravance Biopharma, Inc. Announces Preliminary Results of Tender OfferNovember 11, 2022 | finance.yahoo.comWe Might See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH) SoonNovember 8, 2022 | seekingalpha.comTheravance Biopharma, Inc. (TBPH) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | finance.yahoo.comTheravance (TBPH) Q3 Loss Narrower Than Expected, Sales MissNovember 4, 2022 | msn.comA Preview Of Theravance Biopharma's EarningsNovember 2, 2022 | finance.yahoo.comAmpreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous SystemOctober 31, 2022 | finance.yahoo.comTheravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022October 25, 2022 | finance.yahoo.comTheravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous SystemSeptember 29, 2022 | finanznachrichten.deTheravance Biopharma, Inc.: Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary SharesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address TBPH Company Calendar Last Earnings11/02/2021Today3/25/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CUSIPN/A CIK1583107 Webwww.theravance.com Phone(650) 808-6000FaxN/AEmployees359Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.50 High Stock Price Forecast$19.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+56.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$11.54 Trailing P/E Ratio0.91 Forward P/E RatioN/A P/E GrowthN/ANet Income$872.13 million Net Margins1,698.54% Pretax Margin-180.76% Return on Equity-93.49% Return on Assets-9.91% Debt Debt-to-Equity RatioN/A Current Ratio12.31 Quick Ratio12.31 Sales & Book Value Annual Sales$51.35 million Price / Sales12.95 Cash FlowN/A Price / Cash FlowN/A Book Value$6.56 per share Price / Book1.60Miscellaneous Outstanding Shares63,230,000Free Float60,191,000Market Cap$665.18 million OptionableOptionable Beta0.51 Key ExecutivesRick E. WinninghamChairman & Chief Executive OfficerAndrew Asa HindmanChief Financial Officer & Senior Vice PresidentVijay SabesanSenior Vice President-Technical OperationsPhilip D. WorboysSenior VP-Research & Translational ScienceBradford J. ShaferSecretary, Executive VP & General CounselKey CompetitorsTyra BiosciencesNASDAQ:TYRADyne TherapeuticsNASDAQ:DYNAmarinNASDAQ:AMRNArcutis BiotherapeuticsNASDAQ:ARQTRAPT TherapeuticsNASDAQ:RAPTView All CompetitorsInsiders & InstitutionsRichard A GrahamSold 2,323 sharesTotal: $23,973.36 ($10.32/share)Rhonda FarnumSold 4,000 sharesTotal: $40,800.00 ($10.20/share)Richard A GrahamSold 2,323 sharesTotal: $23,346.15 ($10.05/share)Macquarie Group Ltd.Sold 5,296 shares on 2/21/2023Ownership: 0.310%Point72 Middle East FZEBought 3,649 shares on 2/16/2023Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions TBPH Stock - Frequently Asked Questions Should I buy or sell Theravance Biopharma stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TBPH shares. View TBPH analyst ratings or view top-rated stocks. What is Theravance Biopharma's stock price forecast for 2023? 2 brokers have issued twelve-month price targets for Theravance Biopharma's shares. Their TBPH share price forecasts range from $14.00 to $19.00. On average, they anticipate the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price. View analysts price targets for TBPH or view top-rated stocks among Wall Street analysts. How have TBPH shares performed in 2023? Theravance Biopharma's stock was trading at $11.22 at the beginning of the year. Since then, TBPH stock has decreased by 6.2% and is now trading at $10.52. View the best growth stocks for 2023 here. When is Theravance Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our TBPH earnings forecast. How were Theravance Biopharma's earnings last quarter? Theravance Biopharma, Inc. (NASDAQ:TBPH) released its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.12. The biopharmaceutical company had revenue of $13.19 million for the quarter, compared to analyst estimates of $13.55 million. Theravance Biopharma had a negative trailing twelve-month return on equity of 93.49% and a net margin of 1,698.54%. During the same period last year, the company earned ($1.16) EPS. What ETFs hold Theravance Biopharma's stock? ETFs with the largest weight of Theravance Biopharma (NASDAQ:TBPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Pharmaceuticals ETF (XPH), Global X Aging Population ETF (AGNG), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC) and iShares Micro-Cap ETF (IWC). What other stocks do shareholders of Theravance Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX). What is Theravance Biopharma's stock symbol? Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH." Who are Theravance Biopharma's major shareholders? Theravance Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (1.69%), Two Sigma Investments LP (1.43%), Bank of America Corp DE (1.30%), Millennium Management LLC (1.00%), Norges Bank (0.81%) and Charles Schwab Investment Management Inc. (0.77%). Insiders that own company stock include Brett K Haumann, Philip D Worboys, Rhonda Farnum, Richard A Graham and Rick E Winningham. View institutional ownership trends. How do I buy shares of Theravance Biopharma? Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Theravance Biopharma's stock price today? One share of TBPH stock can currently be purchased for approximately $10.52. How much money does Theravance Biopharma make? Theravance Biopharma (NASDAQ:TBPH) has a market capitalization of $665.18 million and generates $51.35 million in revenue each year. The biopharmaceutical company earns $872.13 million in net income (profit) each year or $11.54 on an earnings per share basis. How many employees does Theravance Biopharma have? The company employs 359 workers across the globe. How can I contact Theravance Biopharma? Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The official website for the company is www.theravance.com. The biopharmaceutical company can be reached via phone at (650) 808-6000 or via email at investor.relations@theravance.com. This page (NASDAQ:TBPH) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.